AMPK activator
AICAR
AICAR (acadesine) given intravenously to 3,080 cardiac surgery patients matched placebo on the primary outcome (5.1% against 5.0%), and the app lists a half-life of 1 hour.1
AICAR after one dose: 50% at ~1 h, 25% at 2 h, 12.5% at 3 h.
Drawn from the half-life in the app's model, ~1 h. The model's figures
- Compound
- AICAR
- Symbol
- AIC
- Family
- Metabolic and mitochondrial peptides
- Parts
- 13
- References
- 10
- Checked
- Last reviewed . Sources are listed below.
Overview
The app's entry lists AICAR under the names acadesine, AICA riboside and GP-1-110, and files it as an AMPK activator in the metabolic category. Dixon and colleagues at Gensia Pharmaceuticals, in the Journal of Clinical Pharmacology in 1993, describe acadesine as "a purine nucleoside analog with anti-ischemic properties".2 The app grades the evidence for AICAR as limited. The human studies identified gave acadesine by intravenous infusion in coronary artery bypass graft (CABG) surgery (Mangano and colleagues, Journal of the American College of Cardiology, 2006; Newman and colleagues, JAMA, 2012) and in relapsed or refractory chronic lymphocytic leukemia (Van Den Neste and colleagues, Cancer Chemotherapy and Pharmacology, 2013).3,1,4 Two further studies measured muscle glucose uptake during AICAR in men (Cuthbertson and colleagues, Diabetes, 2007; Babraj and colleagues, American Journal of Physiology Endocrinology and Metabolism, 2009).5,6 In mice, Narkar and colleagues at the Salk Institute reported in Cell in 2008 that 4 weeks of AICAR in sedentary animals was followed by treadmill running about 23% longer and about 44% further than in vehicle-treated mice.7 Searches of PubMed and ClinicalTrials.gov did not identify a trial of AICAR for endurance in people, and the ClinicalTrials.gov records returned for "AICAR" included no fat-loss trial.
How it works
Van Den Neste and colleagues write that "When added to cell cultures or administered to animals or humans, acadesine is phosphorylated to its ribotide, AICA-ribotide (ZMP)", and describe ZMP as "a natural endogenous intermediate in the de novo purine nucleotide biosynthesis".4 In four healthy males given radiolabelled acadesine intravenously, "Uric acid, the end product of purine metabolism in humans, was the major metabolite of acadesine in plasma", and the nucleotide acadesine 5'-monophosphate, confined to red blood cells, "represented 30% of the total blood 14C at the end of the infusion".2 In the mouse experiments, AICAR "increased phosphorylation of AMPK α subunit and acetyl CoA carboxylase (ACC)" in quadriceps, and in primary muscle cells "AICAR failed to increase the expression of the above genes in PPARδ null cells", which the authors describe as demonstrating a requirement of the receptor for transcriptional effects of AMPK on oxidative genes.7 In healthy men, Cuthbertson and colleagues report that "AMPK alpha(1) and alpha(2) activity or AMPK phosphorylation was unchanged after 20 min or 3 h of AICAR" while phosphorylation of extracellular signal-regulated kinase 1/2 increased.5 Babraj and colleagues write that "it may be likely that activation of AMPK is only transient or that the magnitude of the rise was beyond the sensitivity of our current techniques rather than the effect being AMPK independent".6
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~1 h
- Bioavailability
- 5%
- Typical dose
- 50–100 mg/day
- Route
- SubQ, oral
- Time to peak
- ~0.5 h
Sources in this part
The middle column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~1 h | After a 15-minute intravenous infusion of 25 mg/kg radiolabelled acadesine in 4 healthy males, total radioactivity had a terminal phase with an apparent half-life of about 1 week, while intact acadesine was measurable for 2 hours;2 in the leukemia trial with 4-hour infusions, the median acadesine half-life was 5.2 h at 50 mg/kg (6 patients, range 1.0 to 45.4 h) and 16.2 h at 210 mg/kg (3 patients, range 10.2 to 35.7 h)4 |
| Bioavailability | 5% | An intravenous study reports that "Only 5% of the dose was excreted in urine as intact acadesine", which is a measure of urinary recovery after infusion and not of oral absorption;2 no measurement of oral or subcutaneous bioavailability in people was identified |
| Time to peak | ~0.5 h | In the leukemia trial "Maximum acadesine concentrations were observed at the end of the infusions", with median times of maximum concentration of 4.0 to 4.5 h in the single-dose cohorts of 4-hour infusions4 |
| Clearance and distribution | Not listed | Total plasma clearance of 2.2 ± 0.2 L/hour/kg, a blood/plasma ratio of unity and plasma protein binding of approximately 1% after 25 mg/kg intravenously; 48% of the radiolabelled dose was recovered in urine and feces over 2 weeks2 |
In the leukemia trial, ZMP in whole blood had a median half-life of 72.3 h at 50 mg/kg (range 0.5 to 239.9 h), and blood ZMP concentrations reached the lower limit of quantification "between 5 and 22 days after administration".4 The authors write that "The results indicate a high degree of inter-subject variability", and name the underlying disease, comorbidities and co-medication as possible contributors.4
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Newman and colleagues, RED-CABG, JAMA 20121,8 | Randomized, double-blind, placebo-controlled, parallel-group; Merck Sharp & Dohme LLC lead sponsor; stopped after a futility analysis | 3,080 randomized (1493 per group in the primary count); intermediate- to high-risk adults, median age 66, nonemergency on-pump CABG; 300 sites in 7 countries | Acadesine 0.1 mg/kg per minute for 7 hours intravenously, also added to cardioplegic solutions, or placebo; outcomes through day 28 | Composite of all-cause death, nonfatal stroke or mechanical support for severe left ventricular dysfunction: 76 of 1493 (5.1%) on acadesine against 75 of 1493 (5.0%) on placebo, odds ratio 1.01 (95% CI 0.73-1.41); no differences in key secondary end points |
| Mangano and colleagues, McSPI, Journal of the American College of Cardiology 20063 | Randomized, placebo-controlled, 54 institutions; mortality analysis of patients with post-reperfusion myocardial infarction | 2,698 CABG patients (placebo 1,346; acadesine 1,352); 100 had a perioperative myocardial infarction | Acadesine 0.1 mg/kg/min intravenously for 7 h plus 5 µg/ml in cardioplegia solution, or placebo; vital status over 2 years | Two-year mortality after infarction 27.8% (15 of 54) on placebo against 6.5% (3 of 46) on acadesine, p = 0.006, in the subgroup with infarction |
| Van Den Neste and colleagues, Cancer Chemotherapy and Pharmacology 20134 | Phase I/II, open-label, dose escalation; safety and tolerability the primary endpoint | 24 patients with relapsed or refractory chronic lymphocytic leukemia, aged 56 to 79 | Part I: single 4-hour intravenous doses of 50 to 315 mg/kg (n = 18); Part II: 2 or 5 doses of 210 mg/kg (n = 6) | Maximum tolerated dose 210 mg/kg; 2 of 3 patients at 315 mg/kg had a dose-limiting toxicity; hyperuricemia, transient anemia or thrombocytopenia, renal impairment and transient hypotension reported; no conventional IWG responses, with such assessments not prospectively planned; 16 of 24 had a reduction of more than 20% in B-cell count or palpable nodes, and the authors write that the study size is too small to draw definitive conclusions |
| Cuthbertson and colleagues, Diabetes 20075 | Controlled clinical trial (publication type); AICAR and bicycle exercise compared for muscle glucose uptake | 29 healthy men, aged 26 ± 8 years | AICAR dose not given in the retrieved record; measurements at 20 min and 3 h | After 3 h, muscle 2-deoxyglucose uptake rose 2.1 ± 0.8-fold with AICAR and 4.7 ± 1.7-fold with bicycle exercise; whole-body glucose disposal rose 7%; AMPK activity unchanged |
| Babraj and colleagues, American Journal of Physiology Endocrinology and Metabolism 20096 | Infusion study in three groups, with muscle biopsies at 0, 3 and 6 h | 6 young healthy, 8 older and 8 type 2 diabetes participants | AICAR 10 or 20 mg/kg/h intravenously from 3 to 6 h of a 6-h 2-deoxyglucose infusion | At 10 mg/kg/h, 2-deoxyglucose uptake rose 2.9 ± 0.7-fold in young men, 1.8 ± 0.2-fold in older men and 1.6 ± 0.1-fold in men with type 2 diabetes; at 20 mg/kg/h, 2.5 ± 0.1-fold in older men and 2.2 ± 0.2-fold in men with type 2 diabetes; AMPK activity unchanged |
| Dixon and colleagues, Journal of Clinical Pharmacology 19932 | Disposition and metabolism study with radiolabelled acadesine | 4 healthy males | 25 mg/kg of 2-14C-acadesine by 15-minute intravenous infusion | Terminal apparent half-life of total radioactivity about 1 week; intact acadesine measurable for 2 hours; uric acid the major plasma metabolite |
The registry entry NCT00168519 (Baker Heart Research Institute, status completed) lists AICAR among its interventions; no results from it were retrieved.9
Deeper analysis: RED-CABG (Newman and colleagues, JAMA 2012)
Newman and colleagues, writing for the RED-CABG Steering Committee and Investigators with the first author at the Duke Clinical Research Institute, report a "randomized, double-blind, placebo-controlled, parallel-group evaluation of intermediate- to high-risk patients (median age, 66 years) undergoing nonemergency, on-pump CABG surgery at 300 sites in 7 countries".1 Participants were randomized 1:1 to acadesine at 0.1 mg/kg per minute for 7 hours or placebo, "both also added to cardioplegic solutions", beginning just before anesthesia induction; the registry entry gives the acadesine amount as 42 mg/kg by intravenous infusion over approximately 7 hours.1,8 The main outcome was a "Composite of all-cause mortality, nonfatal stroke, or need for mechanical support for SLVD during and following CABG surgery through postoperative day 28".1 The report states that "Because results of a prespecified futility analysis indicated a very low likelihood of a statistically significant efficacious outcome, the trial was stopped after 3080 of the originally projected 7500 study participants were randomized".1 The primary outcome occurred in 76 of 1493 participants (5.1%) on acadesine and 75 of 1493 (5.0%) on placebo (odds ratio 1.01, 95% CI 0.73-1.41), and "There were no differences in key secondary end points measured".1 The registry entry posts the intent-to-treat results, with the composite at 4.9% in both groups, all-cause death 1.9% on acadesine against 1.7% on placebo, nonfatal stroke 1.7% in both, and mechanical support for severe left ventricular dysfunction 2.2% against 2.3%.8 The registry's intent-to-treat counts were 1536 on acadesine and 1544 on placebo, against 1493 per group in the published primary count.8,1 In the as-treated safety population, serious adverse events affected 327 of 1442 on acadesine and 329 of 1457 on placebo.8 Other adverse events affected 1154 of 1442 on acadesine and 1189 of 1457 on placebo.8 The registry entry lists Merck Sharp & Dohme LLC as lead sponsor and the Duke Clinical Research Institute as a collaborator, with a data monitoring committee.8 The retrieved PubMed record lists no funding statement, no author disclosures and no section on the authors' own limitations, so author ties to the sponsor are not stated here. The registry entry excluded people with a "History or presence of gout or uric acid nephrolithiasis".8 The authors' stated background is that a meta-analysis of randomized trials had associated perioperative acadesine infusion with "a reduction in early cardiac death, myocardial infarction, and combined adverse cardiac outcomes" in on-pump CABG, and their conclusion is that "acadesine did not reduce the composite of all-cause mortality, nonfatal stroke, or SLVD".1
Deeper analysis: McSPI post-reperfusion infarction analysis (Mangano and colleagues, 2006)
Mangano and colleagues, from the Ischemia Research and Education Foundation in San Bruno, California, randomized 2,698 CABG patients at 54 institutions to placebo (n = 1,346) or acadesine (n = 1,352) by the same 0.1 mg/kg/min, 7-hour intravenous infusion plus cardioplegia solution.3 Myocardial infarction was defined prospectively by new Q-wave plus CK-MB elevation or autopsy evidence, and outcomes were adjudicated centrally.3 Perioperative infarction occurred in 100 patients (3.7%) and carried a 4.2-fold increase in 2-year mortality; among them, mortality was 27.8% (15 of 54) on placebo and 6.5% (3 of 46) on acadesine (p = 0.006).3 The record gives this comparison only for the 100 patients who had an infarction, and states that the benefit was "similar among diverse subsets".3 The authors concluded that acadesine was effective for reducing the severity of acute post-reperfusion infarction.3 The retrieved record contains no funding statement, disclosures or limitations section; RED-CABG, which used the same infusion rate and duration, reported no difference in its primary composite.3,1
Deeper analysis: phase I/II in chronic lymphocytic leukemia (Van Den Neste and colleagues, 2013)
Van Den Neste and colleagues enrolled 24 patients with relapsed or refractory chronic lymphocytic leukemia between January 2008 and January 2011, 15 of them male (63%), who had received between 1 and 13 previous lines of therapy.4 Dose escalation followed a modified Fibonacci design; Part I patients received a single 4-hour intravenous dose of 50 mg/kg (6 patients), 83.5 mg/kg (3), 139.5 mg/kg (3), 210 mg/kg (3) or 315 mg/kg (3), and Part II patients received two doses (days 1 and 4) or five doses (days 1, 4, 8, 11 and 15) of 210 mg/kg.4 The authors write that "Acadesine infusions were well tolerated. No acadesine-related deaths occurred in the study, and no patients withdrew from the study due to AEs".4 In Part I, 78 adverse events were reported in 15 patients (83%), and six serious adverse events occurred in 2 patients at 50 mg/kg and 2 patients at 315 mg/kg; in Part II, 48 adverse events were reported in 6 patients, with no serious adverse events.4 Across the study, "a single CTCAE grade 4 AE was reported (hyperuricemia) and 9 CTCAE grade 3 events (in 6 patients) were reported".4 At 315 mg/kg one patient had tumor lysis syndrome and another renal impairment with increased creatinine, both serious adverse events of grade 3.4 On efficacy, the authors write that "Trends of efficacy such as a reduction of peripheral CLL cells and reduction in lymphadenopathy were observed; however, the results were variable due to the small population and the range of doses tested", and that "Our study size is too small to draw definitive conclusions".4 The retrieved full text has no funding or conflict-of-interest statement; its affiliation list includes Linden Oncology Ltd (Edinburgh) and Advancell Therapeutics (Barcelona), so author ties to a sponsor are not stated in the text retrieved.4
Deeper analysis: muscle glucose uptake in men (Cuthbertson 2007; Babraj 2009)
Cuthbertson and colleagues, University of Dundee and collaborators, studied 29 healthy men and measured muscle 2-deoxyglucose uptake during a primed, continuous infusion, comparing AICAR with bicycle exercise.5 After 3 h, uptake rose 2.1-fold with AICAR and 4.7-fold with exercise; AMPK phosphorylation rose after exercise but not after AICAR, and the authors conclude that "In healthy people, AICAR acutely stimulates muscle 2DG uptake with a minor effect on whole-body glucose disposal".5 The grant listed in the record is from the Wellcome Trust.5 Babraj and colleagues repeated the approach in 6 young, 8 older and 8 type 2 diabetes participants at 10 or 20 mg/kg/h; doubling the infusion rate gave "only a small increase in additional muscle 2DG uptake".6 They conclude that AICAR "at least acutely and at this dose, has only a limited therapeutic effect on older type 2 diabetic skeletal muscle", and that muscle glucose uptake was blunted by age rather than diabetic status.6 They state that "the AICAR infusion was well tolerated and associated, with no reported side effects in ours or other studies", and that total AMPK α activity was measured while individual isoform activity was not.6 The study was supported by grants to the first author from Tenovus Scotland and Anonymous Trust, a Wellcome Trust programme grant and the European Commission.6
Deeper analysis: the mouse endurance study (Narkar and colleagues, Cell 2008)
Narkar and colleagues at the Salk Institute and the Howard Hughes Medical Institute treated male C57B/6J mice with AICAR and measured treadmill running; this is an animal study, not a human one.7 The methods give AICAR as "500mg/kg/day, i.p." for 4 weeks for the running tests, while the summary of the paper calls AICAR an "orally active" agonist.7 AICAR-treated mice "ran longer (∼23%) and further (∼44%) compared to vehicle-treated mice", with lower epididymal fat mass relative to body weight and higher oxygen consumption "without changing body weight".7 The running-endurance comparison used 15 to 20 animals per group in the figure legend, and the summary states that "even in sedentary mice, 4 weeks of AICAR treatment alone induced metabolic genes and enhanced running endurance by 44%".7 The retrieved full text contains no separate section on the authors' limitations, and the grants listed include the Howard Hughes Medical Institute and several NIH institutes.7
Doses reported in studies and on labels
| Study | Dose and route | Duration | Who (n) | Comparator |
|---|---|---|---|---|
| Newman and colleagues, RED-CABG1 | 0.1 mg/kg per minute intravenously, plus acadesine in cardioplegic solutions | 7 hours | Adults having CABG (3,080 randomized) | Placebo |
| Mangano and colleagues3 | 0.1 mg/kg/min intravenously, plus 5 µg/ml in cardioplegia solution | 7 h | 2,698 CABG patients | Placebo |
| Van Den Neste and colleagues, Part I4 | Single intravenous doses of 50, 83.5, 139.5, 210 or 315 mg/kg | One 4-hour infusion | 18 patients with leukemia | None (open-label dose escalation) |
| Van Den Neste and colleagues, Part II4 | 210 mg/kg intravenously, 2 or 5 doses | Days 1 and 4, or days 1, 4, 8, 11 and 15 | 6 patients with leukemia | None |
| Dixon and colleagues2 | 25 mg/kg of radiolabelled acadesine intravenously | 15 minutes | 4 healthy males | None |
| Babraj and colleagues6 | 10 or 20 mg/kg/h intravenous infusion | 3 h (from hour 3 to hour 6) | 6 young, 8 older, 8 type 2 diabetes | Basal uptake in the same participants |
| Narkar and colleagues, mice (animal)7 | 500 mg/kg/day, i.p. (methods); 250 mg/kg/day, i.p. for gene expression | 4 weeks; 6 days | C57B/6J mice, 15 to 20 per group in the running test | Vehicle |
| The app's figure | 50 to 100 mg/day, SubQ or oral | Not listed | Not applicable | Not applicable |
The trial doses were intravenous and set by body weight, while the app's range is in milligrams per day by subcutaneous or oral routes; the studies retrieved report no subcutaneous or oral dose of AICAR in people.
Side effects reported
Sources in this part
- In the leukemia trial, "Grade ≥2 hyperuricemia occurred commonly but was not clinically significant and resolved with the administration of prophylactic allopurinol", and other adverse events included transient anemia or thrombocytopenia, renal impairment and transient infusion-related hypotension.4
- Four of the 24 leukemia patients had renal impairment (two at 315 mg/kg and two at 5 × 210 mg/kg); all recovered and none needed dialysis.4
- At 315 mg/kg, 2 of 3 patients had a dose-limiting toxicity, one a tumor lysis syndrome classed as a serious adverse event of CTCAE grade 3.4
- In RED-CABG, serious adverse events affected 327 of 1442 patients on acadesine and 329 of 1457 on placebo.8
Bloodwork and markers
Sources in this part
The app's marker list for AICAR is liver enzymes, blood glucose and complete blood count. The leukemia trial assessed "changes in laboratory values (including liver enzymes, blood glucose and uric acid)", and reported hyperuricemia, increased creatinine, and grade 1 or 2 anemia and thrombocytopenia.4 In healthy men, whole-body glucose disposal in the euglycemic-hyperinsulinemic clamp rose by 7% during AICAR (from 9.3 ± 0.6 to 10 ± 0.6 mg/kg/min).5
Regulatory and anti-doping status
Sources in this part
The World Anti-Doping Agency's 2026 Prohibited List names AICAR under S4.4.1, "Activators of the AMP-activated protein kinase (AMPK)", in the S4 class of hormone and metabolic modulators.10 S4 substances are "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)", and classes S4.3 and S4.4 are non-Specified Substances.10 Searches of DailyMed for "acadesine" and for "AICAR aminoimidazole carboxamide riboside" returned 0 labels.
What is not known
- The human half-life of AICAR is not settled by the studies retrieved: they report about 1 week for total radioactivity, medians of 3.9 to 98.8 h for acadesine across leukemia cohorts and doses, and the app lists 1 hour.2,4
- No measurement of oral or subcutaneous exposure in people was identified among the PubMed records for "AICAR acadesine pharmacokinetics human plasma", which numbered one, a mouse study, so the app's 5% bioavailability and its oral and subcutaneous routes have no human measurement behind them in the sources retrieved.
- The 44% endurance result is from mice, and in the same paper the route is given as intraperitoneal in the methods and as oral in the summary.7
- Trials in cardiac surgery patients and leukemia patients do not show what AICAR does in healthy people; the studies of healthy men measured muscle glucose uptake, not endurance or fat loss.5,6
Frequently asked questions
What is the half-life of AICAR?
The app lists a half-life of about 1 hour for AICAR. In 4 healthy males, total radioactivity after intravenous radiolabelled acadesine had a terminal apparent half-life of about 1 week, and intact acadesine was measurable for 2 hours.2 In the leukemia trial the median acadesine half-life was 5.2 h at 50 mg/kg (6 patients) and 16.2 h at 210 mg/kg (3 patients).4
Is AICAR banned by WADA?
The World Anti-Doping Agency's 2026 Prohibited List names AICAR under S4.4.1, activators of the AMP-activated protein kinase, which are prohibited at all times.10
Does AICAR improve endurance in humans?
No trial of AICAR for endurance in people was identified in searches of PubMed and ClinicalTrials.gov. The 44% endurance figure comes from mice given AICAR for 4 weeks, as reported by Narkar and colleagues in Cell in 2008.7
What happened in the RED-CABG trial of acadesine?
Has AICAR been given to people by mouth?
What side effects were reported with acadesine in studies?
In a trial of 24 leukemia patients, hyperuricemia, transient anemia or thrombocytopenia, renal impairment and transient infusion-related hypotension were reported at intravenous doses of 50 to 315 mg/kg.4 At 315 mg/kg, 2 of 3 patients had a dose-limiting toxicity, one a tumor lysis syndrome classed as a serious adverse event of CTCAE grade 3.4 In RED-CABG, serious adverse events affected 327 of 1442 patients on acadesine and 329 of 1457 on placebo.8
Does AICAR have a US label?
Searches of DailyMed for "acadesine" and "AICAR aminoimidazole carboxamide riboside" returned 0 labels.
Guides, tools and comparisons
References
- Newman MF, et al. Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial. JAMA 2012;308(2):157-64. PMID 22782417
- Dixon R, et al. Acadesine (AICA-riboside): disposition and metabolism of an adenosine-regulating agent. J Clin Pharmacol 1993;33(10):955-8. PMID 8227467
- Mangano DT, et al. Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine. J Am Coll Cardiol 2006;48(1):206-14. PMID 16814669
- Van Den Neste E, et al. Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study. Cancer Chemother Pharmacol 2013;71(3):581-91. PMC3579463
- Cuthbertson DJ, et al. 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men. Diabetes 2007;56(8):2078-84. PMID 17513706
- Babraj JA, et al. Blunting of AICAR-induced human skeletal muscle glucose uptake in type 2 diabetes is dependent on age rather than diabetic status. Am J Physiol Endocrinol Metab 2009. PMC2681307
- Narkar VA, et al. AMPK and PPARδ agonists are exercise mimetics. Cell 2008. PMC2706130
- Merck Sharp & Dohme LLC. RED-CABG: acadesine in coronary artery bypass graft surgery. ClinicalTrials.gov NCT00872001. NCT00872001
- Baker Heart Research Institute. Contraction (exercise) mediated glucose uptake as a therapeutic target in type 2 diabetes. ClinicalTrials.gov NCT00168519. NCT00168519
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list